Drug intelligence / Profile preview

ND-12

Development stage: Phase 1
Lead developer: The Second Hospital of Nanjing Medical University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

ND-12 is an investigational live biotherapeutic product (LBP) consisting of a specific probiotic strain, currently under development by **The Second Hospital of Nanjing Medical University**. It is being evaluated primarily for the treatment of chronic inflammatory diarrhea and ulcerative colitis. ND-12 is designed to modulate the intestinal microbiota, restore gut homeostasis, and reduce mucosal inflammation. In clinical research, it is often studied as an oral capsule, either as a monotherapy or in combination with other microbial agents such as **H-6**. Clinical trials have compared its efficacy and safety against standard anti-inflammatory treatments like mesalazine in adult populations.

Beyond the preview

Go deeper on ND-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND-12.

Explore the full profile